Metastatic Breast Cancer
ATOSAtossa TherapeuticsCatalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for (Z)-Endoxifen (Estrogen Modulator) in Metastatic Breast Cancer. The expected timing is based on the latest available company guidance and may change.
11/12/25:- Planning IND for Ph2 metastatic breast cancer Q4 2025 with topline data in 2026. 12/15/25:- ESR1 mutant breast cancer data showed strong ERα antagonism and reversal of oncogenic transcriptional signatures. 01/06/26:- FDA issued Study May Proceed for metastatic Ph2; topline data still expected in 2026. 03/25/26:- Company reiterates focus on (Z)-endoxifen metastatic program; no new data or timing changes disclosed. 05/08/26:- Q1 update: metastatic program progressing; higher R&D spend; new breast oncology lead; no new trial data. 05/27/26:- ASCO 2026 abstract shows (Z)-endoxifen ER inhibition across ESR1 mutations. 08/07/26:- ASCO ESR1 mutation data reiterated; 2026 Ph2 topline timing unchanged.
Verification
Confirm timing and program details against the company announcement or filing.